

EXHIBIT C.4

Defendants' Trial Exhibit List

Plaintiffs and Defendants exchanged trial exhibits beginning on December 5, 2014. Plaintiffs, in their initial and supplemental lists of trial exhibits, identified 1,290 exhibits. Defendants, in order to conform to this Court's individual rules of practice, deduplicated any exhibit found on plaintiffs' lists from their own lists exchanged with the plaintiffs. However, at 9 pm on December 31, 2014, Plaintiffs revised their list to remove approximately 600 exhibits. Defendants have made a good-faith effort to respond to this last-minute change by adding exhibits originally identified by Plaintiffs to this list. However, in light of the short timespan and the prejudice that would result to Defendants if Plaintiffs have removed an exhibit from their list that Defendants intended to use themselves but did not identify to avoid duplication, Defendants reserve the right to supplement this list with additional exhibits originally identified by Plaintiffs.

Exhibit Number	Brief Description	Objections
DA-1	Letter from R. Clark to T. Abrams	*
DA-2	Audit Committee Minutes	*
DA-3	Email from L. Fox to A. Waxman re: disclosures	*
DA-4	Email from L. Fox to multiple recipients re: disclosures	*
DA-5	Email from L. Fox to A. Waxman re: certification	*
DA-6	Bextra Presentation	*
DA-7	SEC Certification for David Shedlarz	*
DA-8	Email from L. Fox to multiple recipients re: disclosures	*
DA-9	Executive Litigation Agenda	*
DA-10	2006 Audit Results and SAS 61 Report	*
DA-11	2006 Audit Results and SAS 61 Report	*
DA-12	Stichting Philips Pensioenfonds Quarterly Report	**
DA-13	Agreement between Philips Pensioenfonds and Robbins Geller	**
DA-14	KPMG Workpaper	*
DA-15	Email from L. Fox to J. Kindler re: disclosures	*
DA-16	Email from L. Fox to KPMG NYHD re: disclosures	*
DA-17	Letter from J. Chapman to Pfizer	*
DA-18	KPMG Workpaper	*
DA-19	Letter from A. Waxman, S. Phillips to J. Chapman	*
DA-20	KPMG Workpaper	*
DA-21	Interim Completion Document	*
DA-22	KPMG 2007 Audit Results and SAS 114 Report	*
DA-23	Interim Completion Document	*

Defendants' Trial Exhibit List

DA-24	Interim Completion Document	*
DA-25	Interim Completion Document	*
DA-26	KPMG Workpaper	*
DA-27	Letter from A. Schulman, D. Reid, D. Lankler to L. Bradley	*
DA-28	KPMG Workpaper	*
DA-29	KPMG LLP's Report to the Audit Committee	*
DA-30	Audit Committee Minutes	*
DA-31	Audit Committee Minutes	*
DA-32	Email from D. Lankler to L. Bradley re: Bextra	*
DA-33	Audit Committee Minutes	*
DA-34	Audit Committee Minutes	*
DA-35	KPMG Workpaper	Authenticity + other objections
DA-36	Email from B. Hurd to multiple recipients re: Bextra	*
DA-37	Email from C. Wessel to multiple recipients re: Bextra	*
DA-38	Ropes & Gray Presentation	*
DA-39	Ropes & Gray Presentation	*
DA-40	Schedule 1a Guidelines	**
DA-41	Legal Proceedings Disclosure Process	*
DA-42	KPMG Workpaper	*
DA-43	Pfizer Presentation	*
DA-44	Letter from E. Posner to S. Bloom	*
DA-45	Email from D. Hanson to K. Rendio re: PFE meeting	**
DA-46	Email from D. Lankler to L. Fox re: disclosures	*
DA-47	Email from L. Fox to multiple recipients re: disclosures	*
DA-48	Handwritten notes from D. Block to L. Fox	Authenticity + other objections
DA-49	Email from D. Block to L. Fox re: disclosures	*
DA-50	Email from C. Wessel to L. Fox re: disclosures	*
DB-1	Email from L. Fox to J. Kindler re: disclosures	*
DB-2	Email from L. Fox to J. Chapman re: disclosures	*
DB-3	Email from D. Lankler to C. Wessel re: disclosures	*
DB-4	Email from L. Fox to J. Kindler re: disclosures	*
DB-5	Email from L. Fox to multiple recipients re: disclosures	*
DB-6	Email from L. Fox to D. Lankler re: disclosures	*
DB-7	Email from L. Fox to J. Kindler re: disclosures	*

Defendants' Trial Exhibit List

DB-8	Email from L. Fox to multiple recipients re: disclosures	*
DB-9	Certification Agenda	*
DB-10	Disclosures Controls and Procedures	*
DB-11	Email from L. Fox to multiple recipients re: disclosures	*
DB-12	Email from B. Hurd to multiple recipients re: government investigations	*
DB-13	Email from L. Fox to J. Kindler re: disclosures	*
DB-14	Email from B. Hurd to multiple recipients re: government investigations	*
DB-15	Email from B. Hurd to multiple recipients re: government investigations	*
DB-16	Email from L. Fox to C. Wessel re: disclosures	*
DB-17	Email from L. Fox to multiple recipients re: disclosures	*
DB-18	Email from L. Fox to D. Lankler re: disclosures	*
DB-19	Email from L. Fox to D. Lankler re: disclosures	*
DB-20	Email from D. Block to L. Fox re: disclosures	*
DB-21	Handwritten notes from D. Block to L. Fox	Authenticity + other objections
DB-22	Email from L. Fox to G. Giampetruzzi re: disclosures	Authenticity + other objections
DB-23	Email from L. Fox to A. Waxman re: disclosures	*
DB-24	Email from L. Fox to multiple recipients re: disclosures	*
DB-25	Email from L. Fox to multiple recipients re: disclosures	*
DB-26	Email from B. Hurd to L. Fox re: disclosures	*
DB-27	Email from L. Fox to A. Waxman re: disclosures	*
DB-28	Quarterly Checklist	*
DB-29	Email from G. Capello to L. Fox re: disclosures	*
DB-30	Email from B. Hurd to multiple recipients re: subpoena	*
DB-31	Email from D. Lankler to C. Wessel re: subpoena	*
DB-32	Executive Litigation Agenda	*
DB-33	Handwritten notes	Authenticity + other objections
DB-34	Disclosure Agenda	Authenticity + other objections
DB-35	Email from L. Fox to multiple recipients re: disclosures	*
DB-36	Email from D. Lankler to C. Wessel re: Bextra	*
DB-37	Email from B. Hurd to multiple recipients re: Bextra	*
DB-38	Email from D. Block to C. Wessel re: Bextra	*

Defendants' Trial Exhibit List

DB-39	Email from B. Hurd to multiple recipients re: government investigations	*
DB-40	Email from D. Block to C. Wessel re: disclosures	**
DB-41	Email from L. Fox to A. Waxman re: disclosures	*
DB-42	Email from C. Wessel to D. Block re: Bextra	*
DB-43	Email from D. Block to C. Wessel re: Bextra	*
DB-44	Email from C. Wessel to multiple recipients re: disclosures	*
DB-45	Email from B. Hurd to multiple recipients re: Bextra	*
DB-46	Email from C. Wessel to J. Chapman re: Bextra	*
DB-47	Email from D. Block to P. Brockie re: reserves	*
DB-48	Handwritten notes	Authenticity + other objections
DB-49	Email from R. Witrick to F. D'Amelio re: KPMG	Authenticity + other objections
DB-50	Email from A. Waxman to L. Fox re: disclosures	*
DC-1	Email from D. Lankler to L. Fox re: disclosures	*
DC-2	Email from D. Lankler to C. Wessel re: disclosures	*
DC-3	Email from D. Lankler to L. Fox re: disclosures	*
DC-4	Email from D. Wessel to multiple recipients re: disclosures	*
DC-5	Email from D. Block to L. Fox re: disclosures	Authenticity + other objections
DC-6	Email from L. Fox to S. Phillips re: disclosures	*
DC-7	Email from L. Fox to D. Block re: disclosures	*
DC-8	Email from L. Fox to D. Reid re: disclosures	*
DC-9	Email from B. Hurd to multiple recipients re: Bextra	*
DC-10	Email from L. Fox to D. Lankler re: disclosures	*
DC-11	Email from P. Brockie to multiple recipients re: reserves	*
DC-12	Email from L. Fox to P. Brockie re: disclosures	*
DC-13	Email from K. Dadlani to D. Lankler re: disclosures	*
DC-14	Email from D. Lankler to multiple recipients re: disclosures	*
DC-15	Email from L. Fox to D. Lankler re: disclosures	*
DC-16	Email from G. Giampetruzzi to D. Lankler re: disclosures	*
DC-17	Email from L. Fox to A. Schulman re: disclosures	*
DC-18	Email from L. Fox to A. Schulman re: disclosures	*

Defendants' Trial Exhibit List

DC-19	Email from D. Lankler to G. Giampetruzzi re: disclosures	*
DC-20	Email from G. Giampetruzzi to multiple recipients re: disclosures	*
DC-21	Email from D. Block to G. Giampetruzzi re: disclosures	*
DC-22	Handwritten notes	Authenticity + other objections
DC-23	Email from L. Fox to multiple recipients re: disclosures	*
DC-24	Email from K. Jones to multiple recipients re: reserves	*
DC-25	Email from G. Giampetruzzi to multiple recipients re: Lyrica	*
DC-26	Email from L. Fox to multiple recipients re: disclosures	*
DC-27	Email from L. Fox to multiple recipients re: disclosures	*
DC-28	Email from L. Fox to multiple recipients re: disclosures	*
DC-29	Email from G. Giampetruzzi to multiple recipients re: disclosures	*
DC-30	Email from G. Giampetruzzi to multiple recipients re: disclosures	*
DC-31	Email from D. Lankler to multiple recipients re: Bextra	*
DC-32	Email from D. Lankler to multiple recipients re: Bextra	*
DC-33	Email from D. Lankler to A. Schulman re: Bextra	*
DC-34	Email N. Shannon to D. Lankler re: reserves	Authenticity + other objections
DC-35	Emails from G. Giampetruzzi to D. Block re: Bextra	*
DC-36	Email from D. Lankler to A. Schulman re: ; Bextra	*
DC-37	Email from D. Block to G. Giampetruzzi re: disclosures	*
DC-38	Email from L. Fox to D. Block re: disclosures	*
DC-39	Email from G. Giampetruzzi to multiple recipients re: disclosures	*
DC-40	Email from G. Giampetruzzi to multiple recipients re: Bextra	*
DC-41	Email from P. Brockie to multiple recipients re: reserves	*
DC-42	Email from L. Fox to multiple recipients re: disclosures	*
DC-43	Email from L. Cangialosi to P. Brockie re: Bextra	*
DC-44	Email from G. Giampetruzzi to multiple recipients re: disclosures	*
DC-45	Email from L. Fox to G. Giampetruzzi re: reserves	*

Defendants' Trial Exhibit List

DC-46	Email G. Giampetruzzi to multiple recipients re: Bextra	*
DC-47	Email from L. Fox to multiple recipients re: disclosures	*
DC-48	Legal Proceedings Disclosure Process	*
DC-49	Email from L. Fox to A. Waxman re: disclosures	*
DC-50	Email from L. Fox to S. Phillips re: disclosures	*
DD-1	Quarterly Checklist	*
DD-2	KPMG Workpaper	*
DD-3	KPMG Workpaper	*
DD-4	KPMG Workpaper	*
DD-5	Email from J. Kindler to L. Fox re: disclosures	*
DD-6	KPMG Workpaper	*
DD-7	Legal Proceedings Disclosure Process	Authenticity + other objections
DD-8	KPMG Workpaper	Authenticity + other objections
DD-9	KPMG Workpaper	*
DD-10	KPMG Workpaper	*
DD-11	Letter from A. Waxman to J. Chapman	*
DD-12	Letter from A. Schulman, D. Lankler to L. Bradley	*
DD-13	Email from L. Fox to multiple recipients re: disclosures	*
DD-14	Email from L. Bradley to multiple recipients re: Bextra	*
DD-15	KPMG Workpaper	Authenticity + other objections
DD-16	Draft Letter from J. Kindler to J. Chapman	*
DD-17	Letter from A. Waxman, S. Phillips to KPMG	*
DD-18	Letter from Covington & Burling to D. Cavanagh	Authenticity + other objections
DD-19	KPMG Workpaper	*
DD-20	KPMG Workpaper	Authenticity + other objections
DD-21	KPMG Workpaper	*
DD-22	KPMG Workpaper	*
DD-23	Email from A. Kremer to multiple recipients re: report	*
DD-24	Email from D. Block to G. Giampetruzzi re: reserves	Authenticity + other objections
DD-25	Email from C. Wessel to multiple recipients re: subpoena	*
DD-26	Email from A. Waxman to L. Fox re: disclosures	*
DD-27	Email from M. Levy to multiple recipients re: disclosures	Authenticity + other objections
DD-28	Email from L. Fox to D. Block re: disclosures; Large Pharma Companies re: Bextra and Celebrex	*

Defendants' Trial Exhibit List

DD-29	Email from D. Block to L. Fox re: disclosures	Authenticity + other objections
DD-30	Email from L. Fox to D. Lankler re: disclosures	*
DD-31	Email from L. Fox to multiple recipients re: disclosures	*
DD-32	Email from D. Hipper to L. Fox re: disclosures	Authenticity + other objections
DD-33	Email from A. Waxman to multiple recipients re: disclosures	*
DD-34	Email from D. Block to C. Wessel re: disclosures	*
DD-35	Email from D. Lankler to L. Fox re: disclosures	*
DD-36	Email from D. Lankler to L. Fox re: disclosures	*
DD-37	Email from L. Fox to S. Lee re: disclosures	*
DD-38	Email from L. Fox to J. Chapman re: disclosures	*
DD-39	Email from L. Fox to multiple recipients re: disclosures	*
DD-40	Email from L. Fox to multiple recipients re: disclosures	*
DD-41	Email from D. Block to A. Waxman re: disclosures	*
DD-42	Email from L. Fox to A. Waxman re: disclosures	*
DD-43	Email from C. Wessel to multiple recipients re: subpoenas	*
DD-44	Bextra Presentation	**
DD-45	Ropes & Gray Presentation	*
DD-46	Email from C. Schemitsch to multiple recipients re: internal controls	*
DD-47	Investor Materials	*
DD-48	Email from F. D'Amelio to multiple recipients re: loss causation	*
DD-49	KPMG Workpaper	*
DD-50	KPMG Workpaper	*
DE-1	KPMG Workpaper	*
DE-2	Letter from J. Kindler, A. Waxman to J. Chapman	Authenticity + other objections
DE-3	KPMG Workpaper	*
DE-4	KPMG Workpaper	*
DE-5	KPMG Workpaper	*
DE-6	Memo from J. Murphy, M. Tejwani re: Reserves	*
DE-7	KPMG Workpaper	*
DE-8	KPMG Workpaper	*

Defendants' Trial Exhibit List

DE-9	KPMG Quarterly Review	Authenticity + other objections
DE-10	KPMG Workpaper	Authenticity + other objections
DE-11	KPMG Workpaper; Summary of Account Transactions	*
DE-12	KPMG Workpaper	*
DE-13	Email from P. Brockie to D. Lankler re: Bextra	*
DE-14	Email from P. Brockie to multiple recipients re: Bextra	*
DE-15	Email from P. Brockie to multiple recipients re: reserves	*
DE-16	Financial Executive Litigation Minutes	*
DE-17	Email from P. Brockie to multiple recipients re: disclosures	*
DE-18	Email from L. Cangialosi to multiple recipients re: Bextra	*
DE-19	Email from D. Block to P. Brockie re: reserves	*
DE-20	Executive Litigation Agenda	Authenticity + other objections
DE-21	Executive Litigation Agenda	Authenticity + other objections
DE-22	Executive Litigation Agenda	Authenticity + other objections
DE-23	Email from A. Kremer to multiple recipients re: report	*
DE-24	Memo from A. Waxman and K. Dadlani to Pfizer Litigation Group	*
DE-25	Email from F. D'Amelio to L. Cangialosi re: reserves	*
DE-26	Email from G. Giampetruzzi to D. Lankler re: KPMG	*
DE-27	Email from L. Fox to F. D'Amelio re: disclosures	*
DE-28	Email from J. Kindler to L. Horowitz re: script	*
DE-29	Email from L. Fox to multiple recipients re: disclosures	Authenticity + other objections
DE-30	Allen Waxman Certification	*
DE-31	Memo from J. Kindler to Audit Committee re: compliance	*
DE-32	Audit Committee Minutes	*
DE-33	Alan Levin Certification	**
DE-34	KPMG Workpaper	*
DE-35	L. Cangialosi Certification	*
DE-36	Disclosure Committee Meeting Minutes	*
DE-37	Disclosure Committee Meeting Minutes	*
DE-38	Disclosure Committee Meeting Minutes	*
DE-39	Disclosure Committee Meeting Minutes	*

Defendants' Trial Exhibit List

DE-40	Disclosure Committee Meeting Minutes	*
DE-41	Disclosure Committee Meeting Minutes	*
DE-42	Disclosure Committee Meeting Minutes	*
DE-43	Disclosure Committee Meeting Minutes	*
DE-44	Disclosure Committee Meeting Minutes	*
DE-45	Disclosure Committee Meeting Minutes	*
DE-46	Disclosure Committee Meeting Minutes	*
DE-47	Disclosure Committee Meeting Minutes	*
DE-48	Disclosure Committee Meeting Minutes	*
DE-49	Disclosure Committee Meeting Minutes	*
DE-50	Disclosure Committee Meeting Minutes	*
DF-1	Disclosure Committee Meeting Minutes	*
DF-2	Disclosure Committee Meeting Minutes	*
DF-3	Disclosure Committee Meeting Minutes	*
DF-4	Disclosure Committee Meeting Minutes	*
DF-5	Disclosure Committee Meeting Minutes	*
DF-6	Disclosure Committee Meeting Minutes	*
DF-7	L. Cangialosi Certification	*
DF-8	L. Cangialosi Certification	*
DF-9	L. Cangialosi Certification	*
DF-10	L. Cangialosi Certification	*
DF-11	L. Cangialosi Certification	*
DF-12	L. Cangialosi Certification	*
DF-13	L. Cangialosi Certification	*
DF-14	L. Cangialosi Certification	*
DF-15	L. Cangialosi Certification	*
DF-16	L. Cangialosi Certification	*
DF-17	L. Cangialosi Certification	*
DF-18	L. Cangialosi Certification	*
DF-19	Certification Meeting Minutes	*
DF-20	Certification Meeting Minutes	*
DF-21	Certification Meeting Minutes	*
DF-22	Certification Meeting Minutes	*
DF-23	Certification Meeting Minutes	*

Defendants' Trial Exhibit List

DF-24	Certification Meeting Minutes	*
DF-25	Certification Meeting Minutes	*
DF-26	Certification Meeting Minutes	*
DF-27	Certification Meeting Minutes	*
DF-28	Certification Meeting Minutes	*
DF-29	Certification Meeting Minutes	*
DF-30	L. Cangialosi Certification	*
DF-31	L. Cangialosi Certification	*
DF-32	L. Cangialosi Certification	*
DF-33	L. Cangialosi Certification	*
DF-34	L. Cangialosi Certification	*
DF-35	L. Cangialosi Certification	*
DF-36	L. Cangialosi Certification	*
DF-37	L. Cangialosi Certification	*
DF-38	L. Cangialosi Certification	*
DF-39	L. Cangialosi Certification	*
DF-40	L. Cangialosi Certification	*
DF-41	L. Cangialosi Certification	*
DF-42	Dennis Block Certification	*
DF-43	Dennis Block Certification	*
DF-44	Dennis Block Certification	*
DF-45	Dennis Block Certification	*
DF-46	Dennis Block Certification	*
DF-47	Dennis Block Certification	*
DF-48	Dennis Block Certification	*
DF-49	Dennis Block Certification	*
DF-50	Dennis Block Certification	*
DG-1	Dennis Block Certification	*
DG-2	Dennis Block Certification	*
DG-3	Dennis Block Certification	*
DG-4	Dennis Block Certification	*
DG-5	Letter from E. Posner to M. Tejwani	Authenticity + other objections
DG-6	Letter from E. Posner to KPMG	Authenticity + other objections
DG-7	Letter from E. Posner to H. Cohen	Authenticity + other objections

Defendants' Trial Exhibit List

DG-8	Letter from E. Posner to H. Cohen	Authenticity + other objections
DG-9	Bextra Presentation	*
DG-10	Email from D. Lankler to L. Fox re: disclosures	*
DG-11	Email from L. Fox to J. Chapman re: disclosures	*
DG-12	Legal Proceedings Disclosure Process	*
DG-13	Disclosure Committee Meeting Minutes	*
DG-14	Email from L. Fox to multiple recipients re: disclosures	*
DG-15	Quarterly Checklist	*
DG-16	Quarterly Checklist	*
DG-17	Quarterly Checklist	*
DG-18	Quarterly Checklist	*
DG-19	Quarterly Checklist	*
DG-20	Quarterly Checklist	*
DG-21	Quarterly Checklist	*
DG-22	Email from L. Fox to multiple recipients re: disclosures	*
DG-23	Email from L. Fox to multiple recipients re: disclosures	*
DG-24	Email from L. Fox to multiple recipients re: disclosures	*
DG-25	Email from L. Fox to multiple recipients re: disclosures	*
DG-26	Email from G. Capello to multiple recipients re: disclosures	*
DG-27	Email from D. Block to L. Fox re: disclosures	*
DG-28	Email from A. Waxman to L. Fox re: disclosures	*
DG-29	Email from J. Kindler to L. Fox re: disclosures	*
DG-30	Email from L. Fox to multiple recipients re: disclosures	*
DG-31	Email from C. Wessel to D. Lankler re: Bextra	*
DG-32	KPMG Workpaper	Authenticity + other objections
DG-33	KPMG Workpaper	*
DG-34	Email from C. Mangano to multiple recipients re: disclosures	*
DG-35	Email from M. Benderman to multiple recipients re: disclosures	*
DG-36	Email from J. Kindler to L. Fox re: disclosures	*
DG-37	Email from D. Block to L. Fox re: disclosures	*
DG-38	Email from A. Waxman to L. Fox re: disclosures;	*

Defendants' Trial Exhibit List

DG-39	Email from L. Fox to J. Chapman re: disclosures	*
DG-40	Email from L. Fox to multiple recipients re: disclosures	*
DG-41	Email from L. Fox to multiple recipients re: disclosures	*
DG-42	Email from L. Fox to G. Capello re: disclosures	*
DG-43	Email from L. Fox to multiple recipients re: disclosures	*
DG-44	Email from P. Brockie to K. Dadlani re: Bextra	*
DG-45	Email from S. Harnett to L. Cangialosi re: Bextra	*
DG-46	Email from F. D'Amelio to L. Cangialosi re: Bextra	*
DG-47	Email from L. Fox to L. Bradley re: disclosures	*
DG-48	Email from L. Fox to D. Block re: disclosures	*
DG-49	Email from L. Fox to D. Block re: disclosures	*
DG-50	Email from L. Fox to multiple recipients re: disclosures	*
DH-1	Email from L. Fox to multiple recipients re: disclosures	*
DH-2	Email from L. Fox to multiple recipients re: disclosures	*
DH-3	Email from L. Fox to multiple recipients re: disclosures	*
DH-4	Email from L. Fox to multiple recipients re: disclosures	*
DH-5	Email from L. Fox to multiple recipients re: disclosures	*
DH-6	Quarterly Checklist	*
DH-7	Email from L. Fox to multiple recipients re: disclosures	*
DH-8	Email from A. Waxman to J. Chapman re: disclosures	*
DH-9	Email from C. Wessel to B. Hurd re: Bextra	*
DH-10	Email from D. Block to A. Schulman re: disclosures	*
DH-11	Email from D. Block to L. Fox re: disclosures	Authenticity + other objections
DH-12	Email from L. Fox to multiple recipients re: disclosures	*
DH-13	Email from C. Wessel to multiple recipients re: disclosures	*
DH-14	Email from L. Fox to multiple recipients re: disclosures	*
DH-15	Email from L. Fox to multiple recipients re: disclosures	*
DH-16	Email from L. Fox to D. Block re: disclosures	*
DH-17	Email from L. Fox to multiple recipients re: disclosures	*
DH-18	Email from L. Fox to A. Waxman re: disclosures	*
DH-19	Email from L. Fox to multiple recipients re: disclosures	*
DH-20	Email from L. Fox to A. Waxman re: disclosures	*
DH-21	Email from L. Fox to multiple recipients re: disclosures	*

Defendants' Trial Exhibit List

DH-22	Email from L. Fox to multiple recipients re: disclosures	*
DH-23	Email from G. Capello to A. Waxman re: disclosures	*
DH-24	Email from D. Block to multiple recipients re: disclosures	*
DH-25	Email from G. Capello to multiple recipients re: disclosures	*
DH-26	Email from L. Fox to multiple recipients re: disclosures	*
DH-27	Email from D. Block to L. Fox re: disclosures	*
DH-28	Email from L. Fox to multiple recipients re: disclosures	*
DH-29	Email from L. Fox to A. Waxman re: disclosures	*
DH-30	Email from L. Fox to multiple recipients re: disclosures	*
DH-31	Email from L. Fox to multiple recipients re: disclosures	*
DH-32	Email from L. Fox to A. Waxman re: disclosures	*
DH-33	Email from L. Fox to multiple recipients re: disclosures	*
DH-34	Email from D. Lankler to multiple recipients re: disclosures	*
DH-35	Email from L. Fox to multiple recipients re: disclosures	*
DH-36	Email from L. Fox to multiple recipients re: disclosures	*
DH-37	Email from L. Fox to multiple recipients re: disclosures	*
DH-38	Email from L. Fox to multiple recipients re: disclosures	*
DH-39	Email from L. Fox to multiple recipients re: disclosures	*
DH-40	Email from L. Fox to multiple recipients re: disclosures	*
DH-41	Email from D. Block to L. Fox re: disclosures	*
DH-42	Email from D. Lankler to L. Fox re: disclosures	*
DH-43	Email from L. Fox to D. Lankler re: Bextra	*
DH-44	Email from L. Fox to D. Lankler re: disclosures	*
DH-45	Email from L. Fox to multiple recipients re: disclosures	*
DH-46	Email from L. Fox to multiple recipients re: disclosures	*
DH-47	Email from L. Fox to multiple recipients re: disclosures	*
DH-48	Email from L. Fox to multiple recipients re: disclosures	*
DH-49	Email from L. Fox to multiple recipients re: disclosures	*
DH-50	Draft Disclosure	Authenticity + other objections
DI-1	Email from L. Fox to A. Waxman re: disclosures	*
DI-2	Draft Disclosure	Authenticity + other objections
DI-3	Draft Disclosure	Authenticity + other objections

Defendants' Trial Exhibit List

DI-4	Email from L. Fox to multiple recipients re: disclosures	*
DI-5	Email from L. Fox to A. Waxman re: disclosures	*
DI-6	Email from A. Waxman to L. Fox re: disclosures	*
DI-7	Email from A. Waxman to multiple recipients re: disclosures	*
DI-8	Email from D. Lankler to A. Schulman re: Bextra	*
DI-9	Email from L. Fox to multiple recipients re: disclosures	*
DI-10	Email from L. Fox to D. Lankler re: disclosures	*
DI-11	Email from L. Fox to multiple recipients re: disclosures	*
DI-12	Email from H. Donnelly to multiple recipients re: disclosures	*
DI-13	Email from J. Martinez to L. Fox re: disclosures	Authenticity + other objections
DI-14	Email from G. Capello to multiple recipients re: disclosures	*
DI-15	Email from D. Block to multiple recipients re: disclosures	*
DI-16	Email from D. Block to C. Wessel re: disclosures	*
DI-17	Audit Committee Minutes	*
DI-18	KPMG Workpaper	*
DI-19	KPMG Workpaper	*
DI-20	KPMG Presentation SAS61 Communications	*
DI-21	Letter from J. Chapman to Pfizer	*
DI-22	Letter from Davis Polk to M. Tejwani	*
DI-23	KPMG Workpaper	Authenticity + other objections
DI-24	Letter from S. Bloom to E. Posner	**
DI-25	KPMG Workpaper	*
DI-26	Dennis Block Certification	*
DI-27	Dennis Block Certification	*
DI-28	Email from W. Mills to multiple recipients re: term sheet	*
DI-29	Email from P. Brockie to D. Lankler re: reserves	*
DI-30	Email from J. Kaskanian to multiple recipients re: Wyeth	*
DI-31	Memo from J. Kindler to Board of Directors re: litigation	*
DI-32	Email from L. Fox to multiple recipients re: disclosures	*
DI-33	Litigation Controls Report	*
DI-34	Litigation Controls Report	*

Defendants' Trial Exhibit List

DI-35	Litigation Controls Report	*
DI-36	Litigation Controls Report	*
DI-37	Litigation Controls Report	*
DI-38	Litigation Controls Report	*
DI-39	Litigation Controls Report	*
DI-40	Litigation Controls Report	*
DI-41	Litigation Controls Report	*
DI-42	Litigation Controls Report	*
DI-43	Litigation Controls Report	*
DI-44	Litigation Controls Report	*
DI-45	Litigation Controls Report	*
DI-46	Litigation Controls Report	*
DI-47	Litigation Controls Report	*
DI-48	Litigation Controls Report	*
DI-49	Litigation Controls Report	*
DI-50	Litigation Controls Report	*
DJ-1	Draft press release	Authenticity + other objections
DJ-2	Douglas Lankler Sub-Certifications	*
DJ-3	Douglas Lankler Sub-Certifications	*
DJ-4	Douglas Lankler Sub-Certifications	*
DJ-5	Douglas Lankler Sub-Certifications	*
DJ-6	Douglas Lankler Sub-Certifications	*
DJ-7	Douglas Lankler Sub-Certifications	*
DJ-8	Kim Dadlani Sub-Certifications	*
DJ-9	Kim Dadlani Sub-Certifications	*
DJ-10	Kim Dadlani Sub-Certifications	*
DJ-11	Kim Dadlani Sub-Certifications	*
DJ-12	Kim Dadlani Sub-Certifications	*
DJ-13	Kim Dadlani Sub-Certifications	*
DJ-14	Memo from A. Waxman to Senior Litigation Attorneys re: certifications	*
DJ-15	Memo from Waxman re: certifications	*
DJ-16	Memo from Waxman re: certifications	*
DJ-17	Allen Waxman Certification	*

Defendants' Trial Exhibit List

DJ-18	Memo from Fox re: certifications	*
DJ-19	Email from S. Beaty to multiple recipients re: meeting	Authenticity + other objections
DJ-20	Email from R. Aldridge to multiple recipients re: analysts	Authenticity + other objections
DJ-21	Letter from C. Mehta to H. Rosen	*
DJ-22	Statement of Financial Accounting Standards No. 5	Authenticity + other objections
DJ-23	Letter from R. Llorens to A. Lamberti	**
DJ-24	News & Media Press Release	Authenticity + other objections
DJ-25	Pfizer Press Release	Authenticity + other objections
DJ-26	Amgen Form 10-K	*
DJ-27	Amgen press release	Authenticity + other objections
DJ-28	Abbott press release	Authenticity + other objections
DJ-29	Eli Lilly and Company Form 10-K	*
DJ-30	Eli Lilly and Company Form 10-Q	*
DJ-31	Merck Form 10-Q	*
DJ-32	Serono S.A. Form 20-F	*
DJ-33	Elan press release	Authenticity + other objections
DJ-34	Elan Form 6-K	*
DJ-35	Eli Lilly press release	Authenticity + other objections
DJ-36	Eli Lilly and Company Form 10-Q	*
DJ-37	Letter from A. Hanish to J. Rosenberg	Authenticity + other objections
DJ-38	Letter from J. Edwards to M. Rocha	Authenticity + other objections
DJ-39	Letter from J. Rosenberg to A. Hanish	Authenticity + other objections
DJ-40	Letter from J. Parker to J. Barlow	Authenticity + other objections
DJ-41	Letter from J. Barlow to J. Parker	*
DJ-42	Merck press release	Authenticity + other objections
DJ-43	Merck Form 10-Q	*
DJ-44	DOJ Press Release re: Eli Lilly	**
DJ-45	DOJ Press Release re: Elan	Authenticity + other objections
DJ-46	DOJ Press Release re: Allergan	Authenticity + other objections
DJ-47	Abbott Laboratories Form 10-Q	*
DJ-48	US v. Caronia, 703 F.3d 149 (2d Cir. Dec. 3, 2012)	*
DJ-49	Pfizer Transcript	*
DJ-50	Pfizer Transcript	*
DK-1	Moody's Investors Service	**

Defendants' Trial Exhibit List

DK-2	Reuters article	**
DK-3	Bloomberg article	Authenticity + other objections
DK-4	Rx Compliance Report	Authenticity + other objections
DK-5	Amihud, Yakov and Kefei Li, "The Declining Information Content of Dividend Announcements and the Effects of Institutional Holdings"	**
DK-6	Proposed SFAS: Disclosure of Certain Loss Contingencies - an amendment of FASB Statements No. 5 and 141®	Authenticity + other objections
DK-7	Amgen Form 10-K	*
DK-8	Amgen Form 10-Q	*
DK-9	In re: Schering-Plough Corporation Securities Litigation, Notice	Authenticity + other objections
DK-10	In re: Schering-Plough Corporation Securities Litigation, Order and Final Judgment	Authenticity + other objections
DK-11	In re: Schering-Plough Corporation Securities Litigation, Order	Authenticity + other objections
DK-12	Citi, "Pancreatic Islet Cell Cancer a Limited opportunity for Sutent"	Authenticity + other objections
DK-13	Abbott Laboratories Form 10-K	*
DK-14	Eli Lilly and Company Form 10-Q	*
DK-15	GSK Form 6-K	*
DK-16	Public Law 107-204	Authenticity + other objections
DK-17	Pfizer Press Release	Authenticity + other objections
DK-18	Amer, Tarek et al. "Between-Auditor Differences in the Interpretation of Probability Phrases"	Authenticity + other objections
DK-19	Aharony, Joseph and Amihud Dotan "A Comparative Analysis of Auditor, Manager and Financial Analyst Interpretations of SFAS 5 Disclosure Guidelines"	Authenticity + other objections
DK-20	Harrison, Kenneth; Tomassini, Lawrence "Judging the probability of a contingent loss: An empirical study"	Authenticity + other objections
DK-21	AU Section 337 : Inquiry of a Client's Lawyer Concerning Litigation, Claims, and Assessments	Authenticity + other objections

Defendants' Trial Exhibit List

DK-22	AU Section 337C: Exhibit II - American Bar Association Statement of Policy Regarding Lawyers' Responses to Auditors' Requests for Information	Authenticity + other objections
DK-23	Letter from J. Rosenberg to F. D'Amelio	Authenticity + other objections
DK-24	Letter from M. Rocha to J. Edwards	Authenticity + other objections
DK-25	Letter from J. Rosenberg to J. Barlow	Authenticity + other objections
DK-26	Letter from J. Rosenberg to D. Rice	Authenticity + other objections
DK-27	Allergan Form 10-K	Authenticity + other objections
DK-28	Allergan Form 10-Q	Authenticity + other objections
DK-29	Allergan Form 10-Q	Authenticity + other objections
DK-30	Eli Lilly and Company Form 10-K	Authenticity + other objections
DK-31	Eli Lilly and Company Form 10-K	Authenticity + other objections
DK-32	Eli Lilly and Company Form 10-Q	Authenticity + other objections
DK-33	Eli Lilly and Company Form 10-Q	Authenticity + other objections
DK-34	Eli Lilly and Company Form 10-Q	Authenticity + other objections
DK-35	Eli Lilly and Company Form 10-Q	Authenticity + other objections
DK-36	Serono Form 6-K	Authenticity + other objections
DK-37	CNBC, Downer of a Drug Deal Video	**
DK-38	FDA Guidance for Industry	Authenticity + other objections
DK-39	FDA Draft Guidance for Industry	Authenticity + other objections
DK-40	FDA Regulatory Information	Authenticity + other objections
DK-41	Jevsevar, David S. "AAOS Approves Updated OA Knee CPG"	Authenticity + other objections
DK-42	AAOS, "Treatment of Osteoarthritis of the Knee"	Authenticity + other objections
DK-43	American Society of Anesthesiologists, "Interventional Pain Management is the Practice of Medicine"	Authenticity + other objections
DK-44	GSK press release	Authenticity + other objections
DK-45	J&J press release	Authenticity + other objections
DK-46	Abbott Press Release; Abbott press release	Authenticity + other objections
DK-47	Eli Lilly press release	Authenticity + other objections
DK-48	Merck press release	Authenticity + other objections
DK-49	Amgen press release	Authenticity + other objections
DK-50	Serono press release	Authenticity + other objections
DL-1	Allergan press release	Authenticity + other objections

Defendants' Trial Exhibit List

DL-2	Schering-Plough Press Release	Authenticity + other objections
DL-3	Bristol-Myers Squibb Press Release	Authenticity + other objections
DL-4	Pfizer Press Release	*
DL-5	AstraZeneca press release	Authenticity + other objections
DL-6	Pfizer Press Release	Authenticity + other objections
DL-7	Cephalon press release	Authenticity + other objections
DL-8	Novartis Press Release	Authenticity + other objections
DL-9	Business Wire article	Authenticity + other objections
DL-10	Business Wire article	Authenticity + other objections
DL-11	PR Newswire article	Authenticity + other objections
DL-12	DOJ Press Release re: Johnson & Johnson	Authenticity + other objections
DL-13	DOJ Press Release re: Merck Sharp & Dohme	Authenticity + other objections
DL-14	DOJ Press Release re: Amgen	Authenticity + other objections
DL-15	DOJ Press Release re: Serono	Authenticity + other objections
DL-16	DOJ Press Release re: Schering	Authenticity + other objections
DL-17	DOJ Press Release re: Bristol-Myers Squibb	Authenticity + other objections
DL-18	DOJ Press Release re: AstraZeneca	Authenticity + other objections
DL-19	DOJ Press Release re: Cephalon	Authenticity + other objections
DL-20	DOJ Press Release re: Novartis	Authenticity + other objections
DL-21	DOJ Press Release re: Forest	Authenticity + other objections
DL-22	DOJ Press Release re: Endo	Authenticity + other objections
DL-23	Letter from S. Cosgrove to J. Rosenberg	Authenticity + other objections
DL-24	Dow Jones News Service article	Authenticity + other objections
DL-25	Bloomberg article	Authenticity + other objections
DL-26	Dow Jones News Service article	Authenticity + other objections
DL-27	Dow Jones News Service article	Authenticity + other objections
DL-28	Dow Jones News Service article	Authenticity + other objections
DL-29	The Wall Street Journal Online article	Authenticity + other objections
DL-30	Dow Jones News Service article	Authenticity + other objections
DL-31	Bristol-Myers Squibb Press Release	Authenticity + other objections
DL-32	Bristol-Myers Squibb Press Release	Authenticity + other objections
DL-33	Bristol-Myers Squibb Press Release	Authenticity + other objections
DL-34	Bristol-Myers Squibb Form 10-K	Authenticity + other objections
DL-35	Schering-Plough Press Release	Authenticity + other objections

Defendants' Trial Exhibit List

DL-36	Schering-Plough Corporation Form 8-K	Authenticity + other objections
DL-37	Schering-Plough Corporation Form 10-K	Authenticity + other objections
DL-38	Associated Press Newswires article	Authenticity + other objections
DL-39	Dow Jones Chinese Financial Wire article	Authenticity + other objections
DL-40	Dow Jones News Service article	Authenticity + other objections
DL-41	Dow Jones News Service article	Authenticity + other objections
DL-42	Dow Jones News Service article	Authenticity + other objections
DL-43	Reuters article	Authenticity + other objections
DL-44	Endo Form 8-K	Authenticity + other objections
DL-45	Institutional Brokers' Estimate System for Pfizer - Annual, 1998 - 2009	Authenticity + other objections
DL-46	Institutional Brokers' Estimate System for Pfizer - Quarterly, 1998 - 2009	Authenticity + other objections
DL-47	Deutsche Bank, "Merger Model update, 4Q Review"	Authenticity + other objections
DL-48	Bernstein Research, "Pfizer: 4Q08 Beats – Overshadowed, of Course, by Low 2009 Guidance and News of Wyeth Acquisition"	Authenticity + other objections
DL-49	Merrill Lynch, "Maintaining Buy but lowering PO"	Authenticity + other objections
DL-50	Credit Suisse, "A Closer Look Reinforces Merits, Upgrade PFE to Outperform"	Authenticity + other objections
DM-1	Citi, "2012 NEWCO Top-Line Assumption of \$70B Looks Unachievable"	Authenticity + other objections
DM-2	Natixis Bleichroeder, "Rolling Out Our Pfizer-Wyeth Model; Lowering Target Price to \$16"	Authenticity + other objections
DM-3	Deutsche Bank, "Press reports PFE likely to buy WYE for \$68bn"	Authenticity + other objections
DM-4	Goldman Sachs, "Moving WYE, PFE to Not Rated"	Authenticity + other objections
DM-5	Jyske Bank, "Pfizer Buys Wyeth"	Authenticity + other objections
DM-6	Barclays Capital, "Recommendation Change, 4Q08 Earnings Results and FY09 Changes"	Authenticity + other objections
DM-7	Goldman Sachs, "Highlights of PFE analyst breakfast"	**
DM-8	Merrill Lynch, "Pfizer agrees to purchase Wyeth for \$68 billion"	Authenticity + other objections
DM-9	AB Alliance, "Wyeth (WYE) : Downgrading from "1" > "2""	Authenticity + other objections

Defendants' Trial Exhibit List

DM-10	AB Alliance, "The Weekly Dose: (Jan. 17 - Jan. 30)"	Authenticity + other objections
DM-11	Citi, "Lipitor and Cholesterol Category Trends for Week Ending 01/23/09"	Authenticity + other objections
DM-12	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 1/23"	Authenticity + other objections
DM-13	First Global, "Update - PFE Wyeth Acquisition"	Authenticity + other objections
DM-14	Credit Suisse, "Healthy Market for Novartis Bonds Bodes Well for PFE"	Authenticity + other objections
DM-15	Citi, "Lipitor and Cholesterol Category Trends for Week Ending 1/30/09"	Authenticity + other objections
DM-16	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 01/30"	Authenticity + other objections
DM-17	Bernstein Research, "Pfizer-Wyeth; EPS Accretion, but What Price"	Authenticity + other objections
DM-18	Leerink Swann, "Upgrading to OP on Valuation; Strategic & Pipeline Optionality Offers Upside"	Authenticity + other objections
DM-19	AB Alliance, "The Weekly Dose: (Feb. 6 - Feb. 13)"	Authenticity + other objections
DM-20	Credit Suisse, "Roche Joins Novartis As Healthy Precedents"	Authenticity + other objections
DM-21	Natixis Bleichroeder, "Seven, Six, Five, Four, Three... Phase 3 Keeps Getting Lighter"	Authenticity + other objections
DM-22	UBS Investment Research, "Another Pipeline Setback-Modest Negative"	Authenticity + other objections
DM-23	Cowen and Company, "Sales, EPS Estimates Reduced on PFE Standalone Basis"	Authenticity + other objections
DM-24	Cowen and Company, "Updated Combined PFE0WYE Model; Still Well below 2012 Targets"	Authenticity + other objections
DM-25	Leerink Swann, "Thoughts on Yesterday's Weakness: Bull & Bear Arguments"	Authenticity + other objections
DM-26	Credit Suisse, "WYE 10-K: Good News, Bad News"	Authenticity + other objections
DM-27	AB Alliance, "The Weekly Dose (Feb. 14 - Feb. 27)"	Authenticity + other objections
DM-28	Leerink Swann, "Two positive Licensing & Co-Promotion Deals Diversify Business & Lowering Costs"	Authenticity + other objections
DM-29	AB Alliance, "The Weekly Dose: (Feb. 28 - Mar. 6)"	Authenticity + other objections

Defendants' Trial Exhibit List

DM-30	Cowen and Company, "Quick Take; Sutent Phase III Stopped Early in Rare Form of Pancreatic Tumors"	Authenticity + other objections
DM-31	Citi, "Lipitor and Cholesterol Category Trends for Week Ending 3/06/09"	Authenticity + other objections
DM-32	Citi, "Lipitor and Cholesterol Category Trends for Week Ending 3/20"	Authenticity + other objections
DM-33	Cowen and Company, "What's New in the 10-K?"	Authenticity + other objections
DM-34	Credit Suisse, "Discontinuation of Highest Dose Bapineuzumab Not Material Negative for PFE/WYE"	Authenticity + other objections
DM-35	Leerink Swann, "Negative Sutent & Bapineuzumab News Disappointing; Our Thesis Remains Intact"	Authenticity + other objections
DM-36	Citi, "Lipitor and Cholesterol Category Trends for Week Ended 3/27"	Authenticity + other objections
DM-37	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 4/03"	Authenticity + other objections
DM-38	Bernstein Research, "Quick Take - GlaxoSmithKline, Pfizer: New HIV/AIDS Agreement May Signal A Change In Priorities for Pfizer"	Authenticity + other objections
DM-39	Deutsche Bank, "Company Alert - PFE To Combine HIV Franchise With GSK -- More Consolidation"	Authenticity + other objections
DM-40	Goldman Sachs, "GSK-PFE create new HIV company-novel template to unlock value"	Authenticity + other objections
DM-41	Natixis Bleichroeder, "Pfizer Gets Creative, Forming an HIV-Focused Company with GSK"	Authenticity + other objections
DM-42	AB Alliance, "The Weekly Dose: (Apr. 10 - Apr. 17)"	Authenticity + other objections
DM-43	AB Alliance, "1Q09 Earnings Schedule: Pharma, Medical Services, and Health IT"	Authenticity + other objections
DM-44	Leerink Swann, "Updated Forecasts Reflect Changes to WYE Estimates & 1Q Fx Impact"	Authenticity + other objections
DM-45	Citi, "Lipitor and Cholesterol Category Trends for Week Ending 4/10"	Authenticity + other objections
DM-46	CITI, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 4/10"	Authenticity + other objections

Defendants' Trial Exhibit List

DM-47	Deutsche Bank, "Company Alert - Modifications to Model, Estimates Unchanged"	Authenticity + other objections
DM-48	Citi, "1Q09 Preview: Focus on FX and Continued Cost Cuts"	Authenticity + other objections
DM-49	AB Alliance, "The Weekly Dose: (Apr. 18 - Apr. 24)"	Authenticity + other objections
DM-50	Credit Suisse, "1Q 09 Earnings First Impressions"	Authenticity + other objections
DN-1	Credit Suisse, "The Second opinion: 1Q 09 Results"	Authenticity + other objections
DN-2	Deutsche Bank, "1Q09 Results - First Take"	Authenticity + other objections
DN-3	Deutsche Bank, "1Q09: Transformation Underway, Beats Estimates"	Authenticity + other objections
DN-4	Goldman Sachs, "1Q09: High-quality beat, ahead on operational execution"	Authenticity + other objections
DN-5	Goldman Sachs, "1Q2009 Quick Comment: Operational gains help Pfizer beat"	Authenticity + other objections
DN-6	J.P. Morgan, "1Q Results First Glance: EPS Beat, Focus on Expense Mgmt - ALERT"	Authenticity + other objections
DN-7	Jyske Bank, "Costs under control but Lipitor disappoints"	Authenticity + other objections
DN-8	Citi, "1Q09 Initial Thoughts: Top-Line Growth Troubling"	Authenticity + other objections
DN-9	UBS Investment Research, "Stronger 1Q09; 2009 Guidance Unchanged"	Authenticity + other objections
DN-10	Leerink Swann, "Q1 Quick Reaction: Solid Results Driven Primarily by Cost Leverage"	Authenticity + other objections
DN-11	Cowen and Company, "Q1 Beat Expectations; Full Year Guidance Reiterated"	Authenticity + other objections
DN-12	Barclays Capital, "Earnings Review/Sales Analysis, Delivers 5 cent beat on costs"	Authenticity + other objections
DN-13	Citi, "1Q09 Post View: \$7.6B NEWCO Revenue Shortfall in 2012"	Authenticity + other objections
DN-14	Hilliard Lyons, "First Quarter Sales Impacted by Currency, Competition, and Generics, Wyeth Acquisition Progressing"	Authenticity + other objections
DN-15	Credit Suisse, "Second Opinion on WYE 1Q09 and Target Price Update for WYE and PFE"	Authenticity + other objections

Defendants' Trial Exhibit List

DN-16	Natixis Bleichroeder, "Top Line Continues to Decelerate; Lowering Price Target To \$13"	Authenticity + other objections
DN-17	Bernstein Research, "Pfizer Beats Q1 EPS, Despite Lower Revenues"	Authenticity + other objections
DN-18	Leerink Swann, "Out-year EPS Estimates Intact Despite Lower Lipitor & Celebrex Forecasts"	Authenticity + other objections
DN-19	First Global, "What Happened Last Quarter - Pfizer Inc"	Authenticity + other objections
DN-20	Cowen and Company, "Quick Take: Eisai Seeks To Terminate Aricept Collaboration Post WYE Merger"	Authenticity + other objections
DN-21	Credit Suisse, "Meeting With Management Reinforces Thesis"	Authenticity + other objections
DN-22	Cowen and Company, "What's New in the 10-Q?"	Authenticity + other objections
DN-23	Leerink Swann, "De Minimus EPS Impact From WYE Protonix PI Ruling"	Authenticity + other objections
DN-24	Credit Suisse, "PFE, WYE 1Q: 2009 10Q Update"	Authenticity + other objections
DN-25	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 5/15"	Authenticity + other objections
DN-26	First Global, "Food for Thought - How a major part of the RoE expansion for global pharma players has nothing to do with improving performance"	Authenticity + other objections
DN-27	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 5/22"	Authenticity + other objections
DN-28	Leerink Swann, "Established Products Business Unit Highlights Positive Operational Changes"	Authenticity + other objections
DN-29	Goldman Sachs, "Highlights from Goldman Healthcare conference"	Authenticity + other objections
DN-30	Citi, "JAK-3 Inhibitor Shows Promise in Rheumatoid Arthritis at EULAR"	Authenticity + other objections
DN-31	Goldman Sachs, "JAK-3: Breakthrough potential but long term safety will be key"	Authenticity + other objections
DN-32	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 6/5"	Authenticity + other objections
DN-33	Leerink Swann, "Solid Ph II JAK3 Data -- Longer-Term Results Will be Key"	Authenticity + other objections

Defendants' Trial Exhibit List

DN-34	Natixis Bleichroeder, "More Positive Efficacy Data on JAK-3, But Safety Questions Remain"	Authenticity + other objections
DN-35	Citi, "Aricept Pediatric Exclusivity Possible, but not Meaningful"	Authenticity + other objections
DN-36	J.P. Morgan, "Mgmt Meeting Highlights; Introducing Pro-Forma Estimates"	Authenticity + other objections
DN-37	BMO Capital Markets, "A Black Box for Chantix and Other Revisions"	Authenticity + other objections
DN-38	Barclays Capital, "Earnings Preview, 2Q Preview"	Authenticity + other objections
DN-39	UBS Investment Research, "Merger Update Monday May be Positive"	Authenticity + other objections
DN-40	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 7/10"	Authenticity + other objections
DN-41	Citi, "2Q09 Initial Thoughts: Top-Line Growth Troubling"	Authenticity + other objections
DN-42	Citi, "2Q09 Post View: Top-Line Growth Troubling"	Authenticity + other objections
DN-43	Deutsche Bank, "2Q09 Results - First take"	Authenticity + other objections
DN-44	Hilliard Lyons, "Revenue Declines Continued. Waiting for Wyeth"	Authenticity + other objections
DN-45	Leerink Swann, "Quick Take; Reports Decent 2Q; Top Line Weak But Solid Cost Mgmt As Expected"	Authenticity + other objections
DN-46	J.P. Morgan, "2Q EPS First Glance: Expenses Remain Under Pressure; Top Line Light - ALERT"	Authenticity + other objections
DN-47	UBS Investment Research, "PFE Beats (Weak Quality), Raises Guidance"	Authenticity + other objections
DN-48	Barclays Capital, "Earning Reviews/Sales Analysis, Aggressive Cost Control"	Authenticity + other objections
DN-49	BMO Capital Markets, "Decent 2Q Results, In Line With Our Estimates"	Authenticity + other objections
DN-50	Credit Suisse, "The Second Opinion & Impact on Pro Forma PFE/WYE"	Authenticity + other objections
DO-1	Leerink Swann, "Lackluster 2Q Sales Increase Focus on Close of WYE Acquisition"	Authenticity + other objections
DO-2	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 7/17"	Authenticity + other objections

Defendants' Trial Exhibit List

DO-3	Citi, "Lyrica, Chantix, Suteent, Toviaz Tracker for Week Ending 7/17"	Authenticity + other objections
DO-4	First Global, "What Happened Last Quarter - Pfizer Inc."	Authenticity + other objections
DO-5	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 7/24"	Authenticity + other objections
DO-6	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 7/24"	Authenticity + other objections
DO-7	UBS Investments Research, "Takeaways from Management Meeting"	Authenticity + other objections
DO-8	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 7/31"	Authenticity + other objections
DO-9	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 7/31"	Authenticity + other objections
DO-10	UBS Investment Research, "Prevnar 13 Review Extension Not Material"	Authenticity + other objections
DO-11	Leerink Swann, "Three Month Extension of Prevnar-13 PDUFA Not Alarming"	Authenticity + other objections
DO-12	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 8/14/09"	Authenticity + other objections
DO-13	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 8/21/09"	Authenticity + other objections
DO-14	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 8/28/09"	Authenticity + other objections
DO-15	Morgan Stanley, "Initiating at OW: P/E Should Expand Ahead of Pipeline"	Authenticity + other objections
DO-16	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 9/04/09"	Authenticity + other objections
DO-17	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 9/04/09"	Authenticity + other objections
DO-18	Leerink Swann, "FDA Approves First Zosyn Generic; Competition Already Factored Into Forecasts"	Authenticity + other objections
DO-19	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 9/11/09"	Authenticity + other objections

Defendants' Trial Exhibit List

DO-20	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 9/11/09"	Authenticity + other objections
DO-21	Deutsche Bank, "Company Alert - PFE-WYE Transaction Expected to Close in Early Q409"	Authenticity + other objections
DO-22	Goldman Sachs, "Global Healthcare Pharmaceuticals: Divergent outlook not reflected in shares: buy PFE, Sell AZN.L"	Authenticity + other objections
DO-23	AB Alliance, "The Weekly Dose: (Sept. 5 - Sept 25)"	Authenticity + other objections
DO-24	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 9/18/09"	Authenticity + other objections
DO-25	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 9/25/09"	Authenticity + other objections
DO-26	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 9/25/09"	Authenticity + other objections
DO-27	Merrill Lynch, "PFE Q3 CY09 Results Preview"	Authenticity + other objections
DO-28	Credit Suisse, "Dividend Expectations Differ"	Authenticity + other objections
DO-29	Merrill Lynch, "WYE Merger to Complete October 15"	Authenticity + other objections
DO-30	Morgan Stanley, "Catalysts to watch"	Authenticity + other objections
DO-31	AB Alliance, "The Weekly Dose: (Sept. 26 - Oct. 16)"	Authenticity + other objections
DO-32	J.P. Morgan, "A New Outlook for the New Pfizer; Resuming Coverage with and Overweight Rating"	Authenticity + other objections
DO-33	Barclays Capital, "Company Update, Oddly Divided Dividend"	Authenticity + other objections
DO-34	UBS Investment Research, "U.S. Pharmaceuticals, 3Q09 Earnings May Be A Positive Catalyst"	Authenticity + other objections
DO-35	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 10/9/09"	Authenticity + other objections
DO-36	Deutsche Bank, "3Q09 results - First Take"	Authenticity + other objections
DO-37	Leerink Swann, "Quick Take: Delivers High Quality 3Q & FY:09 EPS Guidance Increased by \$0.05"	Authenticity + other objections
DO-38	UBS Investment Research, "Beats 3Q On Fair Quality; Guidance Revised"	Authenticity + other objections
DO-39	Citi, "3Q09 Post View; Transparency Is An Issue"	Authenticity + other objections

Defendants' Trial Exhibit List

DO-40	Hilliard Lyons, "Company Reports Third Quarter Results, Completes Acquisition of Wyeth"	Authenticity + other objections
DO-41	Morgan Stanley, "Three Reasons To Own PFE Stock; Updated Models"	Authenticity + other objections
DO-42	Merrill Lynch, "3Q:09 Review - Raising PO; Attn Now on WYE Integration"	Authenticity + other objections
DO-43	First Global, "What Happened Last Quarter - Pfizer Inc"	Authenticity + other objections
DO-44	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 10/16/09"	Authenticity + other objections
DO-45	Deutsche Bank, "3Q09 Review & Model Book - Pharma Is Improving Cash Flows In An Uncertain World"	Authenticity + other objections
DO-46	Soleil Securities, "Recent Pullback Provides Opportunity Ahead of Catalysts - Reiterate Buy & Updating Model Post - Wyeth"	Authenticity + other objections
DO-47	Merrill Lynch, "New R&D Network Announced Ahead Of Schedule"	Authenticity + other objections
DO-48	Goldman Sachs, "Integration Ahead Of Schedule, R&D Consolidation A Positive"	Authenticity + other objections
DO-49	Goldman Sachs, "China Healthcare Trip: Pfizer Best Positioned Of US Pharma"	Authenticity + other objections
DO-50	Merrill Lynch, "PFE Increases Dividend 12.5%"	Authenticity + other objections
DP-1	Atlantic Equities, "Dividend Raised And More To Come..."	Authenticity + other objections
DP-2	Cowen and Company, "PFE/WYE Model Updates Continue To Depict Modest Outlook"	Authenticity + other objections
DP-3	Goldman Sachs, "Pfizer/Wyeth Deal: Strategic logic clear, but only as a first step"	Authenticity + other objections
DP-4	J.P. Morgan, "Pharma M&A: A Catalyst For Further Cost Reductions - ALERT"	Authenticity + other objections
DP-5	Citi, "Lipitor And Cholesterol Category Trends For Week Ending 1/23/09"	Authenticity + other objections
DP-6	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 1/30"	Authenticity + other objections

Defendants' Trial Exhibit List

DP-7	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 2/06"	Authenticity + other objections
DP-8	Citi, "Lipitor and Cholesterol Category Trends For Week Ending 2/6/09"	Authenticity + other objections
DP-9	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 2/13"	Authenticity + other objections
DP-10	Citi, "Our Thoughts On The Discontinuation Of Two Key Phase III Assets"	Authenticity + other objections
DP-11	Citi, "Lipitor and Cholesterol Category Trends For Week Ending 2/13/09"	Authenticity + other objections
DP-12	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker For Week Ending 2/20"	Authenticity + other objections
DP-13	Citi, "Lipitor and Cholesterol Category Trends For Week Ending 2/20/09"	Authenticity + other objections
DP-14	First Global, "Snippet - The Pfizer-Aurobindo Deal"	Authenticity + other objections
DP-15	UBS Investment Research, "Court Ruling Eliminates Potential Benefit"	Authenticity + other objections
DP-16	Goldman Sachs, "Position Long Pfizer (PFE) By Selling Puts; Collect 8% Premium"	Authenticity + other objections
DP-17	Goldman Sachs, "Reinstate rating at Buy (CL): Financial argument alone is enough"	Authenticity + other objections
DP-18	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 2/27"	Authenticity + other objections
DP-19	Citi, "Lipitor and Cholesterol Category Trends for Week Ending 2/27/09"	Authenticity + other objections
DP-20	Goldman Sachs, "Current Stock price implies potential FCF destruction"	Authenticity + other objections
DP-21	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 3/06"	Authenticity + other objections
DP-22	Goldman Sachs, "Debt deal mitigates financing headline risk"	Authenticity + other objections
DP-23	Merrill Lynch, "Upgrading to Overweight - 70%"	Authenticity + other objections
DP-24	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 3/13"	Authenticity + other objections

Defendants' Trial Exhibit List

DP-25	Citi, "Lipitor and Cholesterol Category Trends for Week Ending 3/13"	Authenticity + other objections
DP-26	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 3/20"	Authenticity + other objections
DP-27	UBS Investment Research, "Bapineuzumab Disappointing, But Not Dead"	Authenticity + other objections
DP-28	UBS Investment Research, "Sutent (Cancer) Hits Minor Road Bump"	Authenticity + other objections
DP-29	Hapoalim Securities, "Special Note - Pfizer/ Wyeth Merger Update"	Authenticity + other objections
DP-30	Goldman Sachs, "Meeting with management reinforces our Conviction Buy"	Authenticity + other objections
DP-31	Leerink Swann, "HIV Partnership with GSK Is More Evidence of Creative Thinking at PFE"	Authenticity + other objections
DP-32	UBS Investment Research, "HIV Deal With GSK is a Smart Move"	Authenticity + other objections
DP-33	Leerink Swann, "PFE is Only U. S Pharma Hedged Against Tax "Loophole" Changes Looking Forward"	Authenticity + other objections
DP-34	Barclays Capital, "Earnings Preview, Q1 Preview"	Authenticity + other objections
DP-35	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 4/17"	Authenticity + other objections
DP-36	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 4/17"	Authenticity + other objections
DP-37	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 4/24"	Authenticity + other objections
DP-38	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 4/24"	Authenticity + other objections
DP-39	Credit Suisse, "Tanezumab Data Encouraging, Could Pipeline Offer Upside?"	Authenticity + other objections
DP-40	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DP-41	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 5/1"	Authenticity + other objections
DP-42	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 5/1"	Authenticity + other objections

Defendants' Trial Exhibit List

DP-43	Citi, "Low Probability of Eisai Prevailing in Aricept Change of Control Suit"	Authenticity + other objections
DP-44	Goldman Sachs, "European debt road show next week could remove cash restrictions"	Authenticity + other objections
DP-45	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 5/8"	Authenticity + other objections
DP-46	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 5/8"	Authenticity + other objections
DP-47	UBS Investment Research, "Protonix DoJ Suit Unlikely to Impact Deal"	Authenticity + other objections
DP-48	Barclays Capital, "Company Update, Mgmt Meeting - Neutral/Slightly Positive"	Authenticity + other objections
DP-49	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 5/15"	Authenticity + other objections
DP-50	Goldman Sachs, "European debt offering removes bridge facility overhang"	Authenticity + other objections
DQ-1	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DQ-2	UBS Investment Research, "EU Filings Complete; Merger on Track"	Authenticity + other objections
DQ-3	Citi, "Lipitor & Cholesterol Category Trends for week Ending 5/22"	Authenticity + other objections
DQ-4	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DQ-5	Citi, "1Q09 10Q Review - Dividend Increase on the Horizon"	Authenticity + other objections
DQ-6	Citi, "Toviaz Unlikely to Offset Detrol LA Loss of Exclusivity"	Authenticity + other objections
DQ-7	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 5/29"	Authenticity + other objections
DQ-8	Citi, "Lipitor & Cholesterol Category Trends for Holiday Wk Ending 5/29"	Authenticity + other objections
DQ-9	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DQ-10	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 6/5"	Authenticity + other objections

Defendants' Trial Exhibit List

DQ-11	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 6/12"	Authenticity + other objections
DQ-12	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 6/12"	Authenticity + other objections
DQ-13	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DQ-14	Citi, "Lyrica, Chantix, Sutent, Selzentry Tracker for Week Ending 6/19"	Authenticity + other objections
DQ-15	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 6/19"	Authenticity + other objections
DQ-16	Barclays Capital, "Company Update, Chantix - Headline Risk Continues"	Authenticity + other objections
DQ-17	Citi, "Chantix Benefits Outweigh the Risks"	Authenticity + other objections
DQ-18	Citi, "Sutent Opportunity Narrowing?...All Eyes on Breast & NSCLC Data"	Authenticity + other objections
DQ-19	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DQ-20	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 6/26"	Authenticity + other objections
DQ-21	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 6/26"	Authenticity + other objections
DQ-22	Citi, "FDA Denies Aricept Pediatric Exclusivity"	Authenticity + other objections
DQ-23	Jefferson Research, "Our evaluation of PFE"	Authenticity + other objections
DQ-24	Goldman Sachs, "Dividend Increase Potential unparalleled in industry"	Authenticity + other objections
DQ-25	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 7/3"	Authenticity + other objections
DQ-26	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 7/3"	Authenticity + other objections
DQ-27	UBS Investment Research, "Prevnar 13: Despite Another Potential Wrinkle, We Expect an On-Time Approval"	Authenticity + other objections
DQ-28	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DQ-29	Citi, "2Q09 Earnings Preview: Top-Line Performance Is a Focal Point"	Authenticity + other objections
DQ-30	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 7/10"	Authenticity + other objections

Defendants' Trial Exhibit List

DQ-31	Credit Suisse, "2Q 09 Earnings - The Second Opinion"	Authenticity + other objections
DQ-32	Credit Suisse, "2Q 09 Earnings - The Initial Diagnosis"	Authenticity + other objections
DQ-33	Deutsche Bank, "Guidance Raised, Merger On Track, Double Digit Gr in '10"	Authenticity + other objections
DQ-34	Goldman Sachs, "Raising price target on strong operational execution"	Authenticity + other objections
DQ-35	Goldman Sachs, "2Q2009 First Take: Beat and raise on strong expense controls"	Authenticity + other objections
DQ-36	Jyske Bank, "Impressive cost reduction"	Authenticity + other objections
DQ-37	J.P. Morgan, "2Q/09 Earnings: Lower Sales/ Higher Earnings - Continuing A Trend"	Authenticity + other objections
DQ-38	Natixis Bleichroeder, "Neutral Quarter; Wyeth Acquisition on Track for 2H09"	Authenticity + other objections
DQ-39	J.P. Morgan, "Updating Pro Forma Model Post-WYE Results"	Authenticity + other objections
DQ-40	Argus, "Analyst's Notes"	Authenticity + other objections
DQ-41	BMO Capital Markets, "Pfizer Presented at BMO Capital Markets' "Focus on Healthcare" Conference"	Authenticity + other objections
DQ-42	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DQ-43	Deutsche Bank, "The Future of Dividends - Payouts Likely to Fall With Increased Debt Levels"	Authenticity + other objections
DQ-44	Citi, "2Q09 10-Q Review: Re-Financing Reduces Dividend Limitations"	Authenticity + other objections
DQ-45	Citi, "2012 NEWCO Gap Widening for PFE's Top & Bottom-line Targets"	Authenticity + other objections
DQ-46	Citi, "Lyrice, Chantix, Sutent, Toviaz Tracker for Week Ending 8/7"	Authenticity + other objections
DQ-47	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 8/7"	Authenticity + other objections
DQ-48	Merrill Lynch, "Cash Flow is King - Buy"	Authenticity + other objections
DQ-49	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DQ-50	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 8/14/09"	Authenticity + other objections
DR-1	Cowen and Company, "What's New in the 10-Q?"	Authenticity + other objections

Defendants' Trial Exhibit List

DR-2	Citi, "Lipitor & Cholesterol Category Trends for week Ending 8/21/09"	Authenticity + other objections
DR-3	Jyske Bank, "Wyeth deal is nearing its end"	Authenticity + other objections
DR-4	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DR-5	TheStreet.com Ratings, "Pfizer Inc. Recommendation"	Authenticity + other objections
DR-6	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 8/28/09"	Authenticity + other objections
DR-7	Jefferson Research: "Our Evaluation of PFE"	Authenticity + other objections
DR-8	Merrill Lynch, "WYE Deal Nears the Finish Line"	Authenticity + other objections
DR-9	Cowen and Company, "EPS Estimates Intact But Sales Forecasts Trimmed Post Model Revision"	Authenticity + other objections
DR-10	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DR-11	Citi, "Lipitor & Cholesterol Category Trends for Week Ended 9/18/09"	Authenticity + other objections
DR-12	UBS Investment Research, "China Antitrust Approval - Another Step Forward Towards Deal Closure"	Authenticity + other objections
DR-13	Morgan Stanley, "Flu concerns should drive interest in Prevnar-13"	Authenticity + other objections
DR-14	Deutsche Bank, "The "New" Pfizer - First Step Forward"	Authenticity + other objections
DR-15	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DR-16	Leerink Swann, "Removing Sales of CP-751, 871 from Model After Lung Cancer Trial Halted"	Authenticity + other objections
DR-17	Citi, "Lyrica, Chantix, Sutent, Toviaz Tracker for Week Ending 10/2/09"	Authenticity + other objections
DR-18	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 10/2/09"	Authenticity + other objections
DR-19	Credit Suisse, "Dividend Expectations Manageable"	Authenticity + other objections
DR-20	Deutsche Bank, "Company Alert - PFE-WYE merger set to close on October 15th (tomorrow)"	Authenticity + other objections
DR-21	Barclays Capital, "Earnings Preview, Q3 Preview"	Authenticity + other objections
DR-22	Citi, "3Q09 Preview: Integration Plan & Top-Line Are Key Focal Points"	Authenticity + other objections
DR-23	Jyske Bank, "Wyeth acquisition completed"	Authenticity + other objections
DR-24	Credit Suisse, "Our New Integrated PFE/WYE Model"	Authenticity + other objections

Defendants' Trial Exhibit List

DR-25	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 10/9/09"	Authenticity + other objections
DR-26	Morgan Stanley, "Pprevnar-13 expert call re-cap"	Authenticity + other objections
DR-27	Atlantic Equities, "Q309 Snap: Revenues and earnings well ahead"	Authenticity + other objections
DR-28	Barclays Capital, "Earnings Review/Sales Analysis, PFE Call: WYE Rev. Absence Disappoints"	Authenticity + other objections
DR-29	Cowen and Company, "Q3 Solid; Modest Growth Outlook Keeps Us Neutral On The Stock"	Authenticity + other objections
DR-30	Citi, "3Q09 Initial Thoughts: In Line; Focus is on Integration & Dividend"	Authenticity + other objections
DR-31	Credit Suisse, "3Q 09 Earnings - The Second Opinion"	Authenticity + other objections
DR-32	Credit Suisse, "3Q 09 Earnings - Initial Diagnosis"	Authenticity + other objections
DR-33	Deutsche Bank, "Starting Out On the Right Foot - Reiterate Buy"	Authenticity + other objections
DR-34	Goldman Sachs, "Entering stage 2: Multiple expansion drives 12-month PT to \$22"	Authenticity + other objections
DR-35	Goldman Sachs, "First Take: Good quarter, FY guidance raised for WYE deal"	Authenticity + other objections
DR-36	Jyske Bank, "Anticipations once again exceeded"	Authenticity + other objections
DR-37	J.P. Morgan, "PFE 3Q/09 EPS: Modest EPS Beat; Focus Shifting to Wyeth Details - ALERT"	Authenticity + other objections
DR-38	J.P. Morgan, "3Q EPS: Updating Model Following Topline/Margin Upside"	Authenticity + other objections
DR-39	Merrill Lynch, "Q3 CY09 Results - First Look"	Authenticity + other objections
DR-40	Morgan Stanley, "Quick Comment: Numbers Bumping Higher"	Authenticity + other objections
DR-41	Morgan Stanley, "3Q interest expense explained"	Authenticity + other objections
DR-42	Bernstein Research, "Pfizer: Decent, Uneventful Q3; January Guidance Will Be Heavily Anticipated"	Authenticity + other objections
DR-43	Morgan Stanley, "ACIP meeting positive for Pprevnar 13"	Authenticity + other objections
DR-44	Citi, "Lipitor & Cholesterol Category Trends for Week Ending 10/16/09"	Authenticity + other objections
DR-45	Argus, "Analyst's Notes"	Authenticity + other objections

Defendants' Trial Exhibit List

DR-46	Cowen and Company, "What's New In The 10-Q?"	Authenticity + other objections
DR-47	UBS Investment Research, "Pharmaceuticals: Suspending Coverage of 4 Companies"	Authenticity + other objections
DR-48	Morgan Stanley, "Still expecting positive Prevnar-13 panel"	Authenticity + other objections
DR-49	Merrill Lynch, "No major issues expected at Prevnar 13 Ad Com"	Authenticity + other objections
DR-50	Morgan Stanley, "Prevnar-13 expert call re-cap"	Authenticity + other objections
DS-1	Goldman Sachs, "Prevnar 13 sails through FDA meeting: 10 Yes - 1 No"	Authenticity + other objections
DS-2	J.P. Morgan, "Prevnar 13: Positive Panel Vote - ALERT"	Authenticity + other objections
DS-3	Leerink Swann, "Rapid Conversion & H1N1 Pandemic May Drive Upside Oppt'y for PCV13 in '10"	Authenticity + other objections
DS-4	Barclays Capital, "Company Update, Leveraging Sales and Marketing"	Authenticity + other objections
DS-5	Deutsche Bank, "Company Alert - We Expect PFE to Raise Dividend 10%-20% (\$0.70- \$0.75/yr)	Authenticity + other objections
DS-6	Jyske Bank, "Good opportunity of a dividend increase"	Authenticity + other objections
DS-7	J.P. Morgan, "Dividend Bump, Debt Paydown, And Accelerating Biz Dev Ahead"	Authenticity + other objections
DS-8	Morgan Stanley, "Maintaining assumptions post mgmt visit"	Authenticity + other objections
DS-9	Ford Equity Research, "Pfizer"	Authenticity + other objections
DS-10	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DS-11	Soleil Securities, "Investors Should be Opportunistic on Transient Weakness - Reiterate Buy"	Authenticity + other objections
DS-12	Credit Suisse, "More than a Dividend Story"	Authenticity + other objections
DS-13	Morgan Stanley, "Options Market implying \$0.72 dividend for 2010"	Authenticity + other objections
DS-14	Deutsche Bank, "Company Alert - PFE increases dividend by 12.5%, In line with expectations"	Authenticity + other objections
DS-15	J.P. Morgan, "Dividend Increase A Step Toward Higher Payout - ALERT"	Authenticity + other objections
DS-16	Morgan Stanley, "Premarin Litigation Thoughts"	Authenticity + other objections

Defendants' Trial Exhibit List

DS-17	Soleil Securities, "Increases Dividend to \$0.72 (4& yield), In-Line with Consensus-Reiterate Buy	Authenticity + other objections
DS-18	Jefferson Research, "Our Evaluation of PFE"	Authenticity + other objections
DS-19	BMO Capital Markets, "Another Delay at the FDA"	Authenticity + other objections
DS-20	Raymond James, "Figitumumab (cancer) clinical trials discontinued"	Authenticity + other objections
DS-21	Jefferies International Ltd., "Serono - Room for a New Hand on The Tiller?"	Authenticity + other objections
DS-22	Deutsche Bank, "Serono - Rebif Rebound Offset By Serostim Charge"	Authenticity + other objections
DS-23	Morgan Stanley, "Serono - Disappointing 1Q, With a Negative Surprise"	Authenticity + other objections
DS-24	Morgan Stanley, "Serono - 1Q05 Results Fall Short With Large Legal Provision"	Authenticity + other objections
DS-25	Credit Suisse, "Serono - Then and Now"	Authenticity + other objections
DS-26	Credit Suisse, "Eli Lilly - Short Term Outlook Solid, Future Less Clear"	Authenticity + other objections
DS-27	Natixis Bleichroeder, "Eli Lilly - Let the Debt Begin; Lowering Target Price to \$31"	Authenticity + other objections
DS-28	Natixis Bleichroeder, "Actionable Ideas"	Authenticity + other objections
DS-29	Barclays Capital, "Lilly, Eli - Earnings Review/Sales Analysis, Strong Quarter with Uncertain Future"	Authenticity + other objections
DS-30	Hilliard Lyons, "Eli Lilly and Company - A Very Active Time"	Authenticity + other objections
DS-31	Merrill Lynch, "Shifting to more conserv div rating"	Authenticity + other objections
DS-32	Barclays Capital, "Earnings Preview, 4Q and FY08 Earnings Preview"	Authenticity + other objections
DS-33	Cowen and Company, "Quick Take: Combination Looks Solid For PFE Shareholder; Less So For WYE's"	Authenticity + other objections
DS-34	Leerink Swann, "At \$60B, We Estimate PFE/WYE Deal Accretive With or Without Synergies"	Authenticity + other objections
DS-35	Cowen and Company, "Q2 EPS Beat Estimates On Cost Controls/Tax Rate; No Change In Our Forecasts"	Authenticity + other objections

Defendants' Trial Exhibit List

DS-36	Leerink Swann, "R&D Restructuring Hints at a Potential Driver of EPS Upside in 2010-16"	Authenticity + other objections
DS-37	Credit Suisse, "Eli Lilly - Solid 3Q, IMCL Deal and Effient Remain Top Focus"	Authenticity + other objections
DS-38	Email from J. Brabham to multiple recipients re: Lyrica	**
DS-39	Email from E. Cunningham to multiple recipients re: Lyrica	**
DS-40	Email from R. Gurner to multiple recipients re: Lyrica	**
DS-41	Email from R. Gurner to A. Fibig re: Lyrica	**
DS-42	Powers Business Unit Certification	**
DS-43	Email from K. Katen to Pfizer Sales Force re: Pfizer/Pharmacia Guidelines	**
DS-44	Email from J. Giusti to multiple recipients re: Bextra	**
DS-45	Presentation re: PFE COX-2	**
DS-46	Letter from A. Levin, L. Cangialosi to KPMG	**
DS-47	Audit Committee Minutes	**
DS-48	Email from R. Burch to Cluster A Colleagues re: Bextra	**
DS-49	Bextra and Celebrex Launch Presentation	**
DS-50	Email from G. Adams to multiple recipients re: COX2; re: Update: Approved Selling Materials	**
DT-1	Email from M. Abelardo to N. Collins re: Zyvox	**
DT-2	Draft FDA Teleconference Minutes	**
DT-3	Email from V. Cardon to multiple recipients re: Bextra	**
DT-4	Email from C. Dowd to J. Boutelle, E Tavino re: Bextra	**
DT-5	Internal Audit Report	**
DT-6	Internal Audit Report	**
DT-7	Memo from E. Cotter to The Files re: speakers	**
DT-8	Pfizer Whitepaper	**
DT-9	Internal Audit Report	**
DT-10	L. Fleischmann Certification	*
DT-11	The Field Guide	**
DT-12	L. Fleischmann Certification	*
DT-13	2008 CIA Orange Guide Training	*
DT-14	Meeting Agenda	**

Defendants' Trial Exhibit List

DT-15	Bruce Fleischmann Speech	**
DT-16	Lyrca Presentation	**
DT-17	Rick Burch Speech	**
DT-18	Dear Doctor Letter	**
DT-19	Beth Cowit [Levine] Speech	**
DT-20	J. Friedman Certification	*
DT-21	Email from J. Friedman to US Field re: Geodon	**
DT-22	Email from J. Zgombic to multiple recipients re: Geodon	**
DT-23	Bextra Vid Aid	**
DT-24	Email from L. Levy to multiple recipients re: Bextra	**
DT-25	Email from M. Gavigan to multiple recipients re: Bextra	**
DT-26	Email from Executive Communications re: Bextra	**
DT-27	Email from L. Farstveet to various recipients re: Zyvox	**
DT-28	Email from D. Mahoney to multiple recipients re: Zyvox	**
DT-29	Email from J. Friedman to multiple recipients re: Lyrca	**
DT-30	Email from M. Fuchs to multiple recipients re: compliance	**
DT-31	Specialty Business Unit Certification	*
DT-32	Specialty Business Unit Certification	*
DT-33	Specialty Business Unit Certification	*
DT-34	Email from M. Brown to multiple recipients re: Zyvox	**
DT-35	Email from M. Brown to multiple recipients re: Zyvox	**
DT-36	Email from L. Farstveet to multiple recipients re: Zyvox	**
DT-37	Email from B. Fleischmann to A. Greensmith re: Zyvox	**
DT-38	Email from L. Farstveet to various recipients re: Zyvox	**
DT-39	KPMG Workpaper	**
DT-40	Letter from J. Chapman to Pfizer	**
DT-41	KPMG Workpaper	**
DT-42	KPMG Workpaper	**
DT-43	KPMG Workpaper	**
DT-44	KPMG Workpaper	**
DT-45	KPMG Workpaper	**
DT-46	KPMG Workpaper	**
DT-47	Audit Committee Minutes	**

Defendants' Trial Exhibit List

DT-48	KPMG Workpaper	**
DT-49	KPMG SAS 61 Communications Update	**
DT-50	Memo from C. Mooney re: Internal Controls	**
DU-1	Deficiency Evaluation	**
DU-2	Email from R. Burch to multiple recipients re: Geodon	**
DU-3	Email from C. McAllister to US Field re: compliance	**
DU-4	Email from M. Westlock to R. Hobbs re: Geodon	**
DU-5	Email from I. Read to M. Westlock re: Pfizer	**
DU-6	PHR Field Coaching Guide	**
DU-7	Pfizer Manual	**
DU-8	Email from I. Condon to multiple recipients re: WLF Policy	**
DU-9	Zyvox marketing material	**
DU-10	Zyvox marketing material	Authenticity + other objections
DU-11	Zyvox Correction Ad	**
DU-12	Zyvox marketing material	**
DU-13	Wunderink, R., et al., Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia	Authenticity + other objections
DU-14	Internal Control - Integrated Framework	Authenticity + other objections
DU-15	Internal Audit Report	**
DU-16	Internal Audit Report	**
DU-17	Securities and Exchange Commission Staff Paper	Authenticity + other objections
DU-18	GSK Form 20-F	*
DU-19	GSK Form 20-F	*
DU-20	GSK Form 20-F	*
DU-21	GSK Form 20-F	*
DU-22	GSK Form 20-F	*
DU-23	GSK Form 6-K	*
DU-24	Email from C. Singe to A. Rajaratnam re: Pride Program	**
DU-25	Allergan Form 10-Q	*
DU-26	Bextra Medical Operating Plan	**
DU-27	Allergan Press Release	*
DU-28	Allergan Form 10-Q	*
DU-29	Email from T. Farina to A. Alvarez re: Bextra	**

Defendants' Trial Exhibit List

DU-30	Email from Legal Discovery re: Bextra Document Collection	**
DU-31	Minutes of a Special Meeting of the Board of Directors	**
DU-32	Corporate Integrity Agreement Annual Report, Volume I	**
DU-33	Corporate Integrity Agreement Annual Report, Volume I	**
DU-34	Email from G. Capello to multiple recipients re: disclosures	**
DU-35	Audit Committee Minutes	**
DU-36	KPMG Workpaper	**
DU-37	Internal Audit Report	**
DU-38	Audit Committee Minutes	**
DU-39	Letter from D. Lankler to S. Bloom, M. Riordan	**
DU-40	Whitepaper on Pfizer's Certifications	**
DU-41	Pfizer Presentation	**
DU-42	Ropes & Gray Presentation	**
DU-43	Letter from D. Lankler to S. Bloom, M. Riordan	**
DU-44	Audit Committee Minutes	**
DU-45	Audit Committee pre-read	**
DU-46	Audit Committee pre-read	**
DU-47	Audit Committee pre-read	**
DU-48	Memo from P. Kelly to Audit Committee re: speaker program	**
DU-49	Letter from KPMG to Pfizer	**
DU-50	Letter from J. Chapman to Pfizer	**
DV-1	Pfizer Presentation to KPMG	**
DV-2	Audit Committee Minutes	**
DV-3	KPMG Workpaper	**
DV-4	Audit Committee Minutes	**
DV-5	Compliance Guidelines	**
DV-6	KPMG SAS 61 Communications Update	**
DV-7	Auditing Standard No.5- Appendix B	Authenticity + other objections
DV-8	Auditing Standard No.5- Appendix A	Authenticity + other objections
DV-9	Letter from A. Waxman to J. Chapman	**
DV-10	Audit Committee Minutes	**

Defendants' Trial Exhibit List

DV-11	Compliance Guidelines	**
DV-12	Compliance Guidelines	**
DV-13	Hugh Donnelly Certification	**
DV-14	Hugh Donnelly Certification	**
DV-15	Hugh Donnelly Certification	**
DV-16	Hugh Donnelly Certification	**
DV-17	Hugh Donnelly Certification	**
DV-18	Hugh Donnelly Certification	**
DV-19	Hugh Donnelly Certification	**
DV-20	Hugh Donnelly Certification	**
DV-21	Hugh Donnelly Certification	**
DV-22	Hugh Donnelly Certification	**
DV-23	Hugh Donnelly Certification	**
DV-24	Hugh Donnelly Certification	**
DV-25	Hugh Donnelly Certification	**
DV-26	Corporate Integrity Agreement Annual Report, Volume I	**
DV-27	Email from M. Lawton to multiple recipients re: Lyrica	**
DV-28	Corporate Integrity Agreement Annual Report, Volume II	**
DV-29	Corporate Integrity Agreement Annual Report, Volume III	**
DV-30	Corporate Integrity Agreement Annual Report, Volume II	**
DV-31	Corporate Integrity Agreement Annual Report, Volume III	**
DV-32	Corporate Integrity Agreement Annual Report, Volume II	**
DV-33	Corporate Integrity Agreement Annual Report, Volume III	**
DV-34	Corporate Integrity Agreement Annual Report, Volume I	**
DV-35	Corporate Integrity Agreement Annual Report, Volume II	**
DV-36	Corporate Integrity Agreement Annual Report, Volume III	**
DV-37	GSK Form 20-F	**
DV-38	FDA Warning Letter re: Flonase	Authenticity + other objections
DV-39	FDA Warning Letter re: Flonase	Authenticity + other objections
DV-40	OIG Compliance Program Guidance	Authenticity + other objections

Defendants' Trial Exhibit List

DV-41	Letters between J. Rah and N. Hall	**
DV-42	Letters between J. Rah and N. Hall	**
DV-43	Letters between J. Rah and N. Hall	**
DV-44	Compliance Guidelines	**
DV-45	Pfizer Compliance presentation	**
DV-46	Memo from A. Schulman, D. Lankler to Board of Directors re: compliance	**
DV-47	Internal Audit Report	**
DV-48	Email from R. Johnson to multiple recipients re: internal controls	**
DV-49	Letter from I. Read to Pfizer Audit Committee	**
DV-50	Letter from G. Henninger to Pfizer Audit Committee	**
DW-1	Independent Review Report	**
DW-2	Independent Review Report	**
DW-3	Independent Review Report	**
DW-4	Independent Review Report	**
DW-5	Letter from S. Bloom to E. Posner	**
DW-6	Pfizer Press Release	**
DW-7	Bextra launch video	Authenticity + other objections
DW-8	Lyrice launch video	Authenticity + other objections
DW-9	Pfizer Press Release	Authenticity + other objections
DW-10	Pfizer Form 8-K	**
DW-11	Letter from V. Clavelli to L. Stockbridge	*
DW-12	Board of Directors Meeting Minutes	**
DW-13	Fax from V. Clavelli to L. Stockbridge	*
DW-14	Audit Committee pre-read	**
DW-15	Memo from J. Kindler to Audit Committee re: compliance	**
DW-16	Memo from J. Kindler to Board of Directors re: compliance	**
DW-17	Key Principles Guide	**
DW-18	Healthcare Compliance Overview	**
DW-19	Board of Directors Meeting Minutes	**
DW-20	Compliance Update	**

Defendants' Trial Exhibit List

DW-21	Board of Directors Meeting Minutes	**
DW-22	Audit Committee pre-read	**
DW-23	Audit Committee pre-read	**
DW-24	Pfizer Form 8-K	**
DW-25	Levin Form 4	**
DW-26	Levin Form 4	**
DW-27	Levin Form 4	**
DW-28	Levin Form 4	**
DW-29	Levin Form 4	**
DW-30	Levin Form 4	**
DW-31	Levin Form 4	**
DW-32	Levin Form 4	**
DW-33	Levin Form 4	**
DW-34	Levin Form 4	**
DW-35	Levin Form 4	**
DW-36	Levin Form 4	**
DW-37	Levin Form 4	**
DW-38	Levin Form 4	**
DW-39	Levin Form 4	**
DW-40	Levin Form 4	**
DW-41	Levin Form 4	**
DW-42	Levin Form 4	**
DW-43	Levin Form 4	**
DW-44	Levin Form 4	**
DW-45	Levin Form 4	**
DW-46	Levin Form 4	**
DW-47	Levin Form 4	**
DW-48	Levin Form 4	**
DW-49	Levin Form 4	**
DW-50	Levin Form 4	**
DX-1	Levin Form 4	**
DX-2	Levin Form 4	**
DX-3	Levin Form 4	**
DX-4	Levin Form 4	**

Defendants' Trial Exhibit List

DX-5	Levin Form 4	**
DX-6	Levin Form 4	**
DX-7	Levin Form 4	**
DX-8	Levin Form 4	**
DX-9	Levin Form 4	**
DX-10	Levin Form 4	**
DX-11	Levin Form 4	**
DX-12	Levin Form 4	**
DX-13	Levin Form 4	**
DX-14	Levin Form 4	**
DX-15	Press Release, U.S. Attorney's Office District of Massachusetts, Pfizer Subsidiary Agrees To Plead Guilty For Offering Kickback And Pay \$19.68 Million Criminal Fine, dated April 2, 2007	**
DX-16	Internal Audit Report	**
DX-17	KPMG Workpaper	**
DX-18	GSK Form 20-F	*
DX-19	Email from T. Farina to Reps re: Bextra	**
DX-20	M. Holloway Review of T. Farina	**
DX-21	Email from R. Burch to multiple recipients re: compliance	**
DX-22	Ropes & Gray Presentation	**
DX-23	Dear Colleague Letter	**
DX-24	Email from J. Arendain to M. Piemmons re: speakers	**
DX-25	Email from R. Dave to multiple recipients re: Zyvox	**
DX-26	Email from L. Farstveet to multiple recipients re: Zyvox	**
DX-27	Email from E. Scerpella to K. Greensmith re: Zyvox	**
DX-28	POA re: Bextra	**
DX-29	Email from J. Bezila to multiple recipients re: Bextra	**
DX-30	Bextra Vis Aid	**
DX-31	POA 1 2004 Selling Tips	**
DX-32	Email from J. Dicker to multiple recipients re: Bextra	**
DX-33	Bextra Resource Guide	**
DX-34	Email from F. Bonica to multiple recipients re: Bextra	**
DX-35	Bextra Launch Transcript	**

Defendants' Trial Exhibit List

DX-36	Healthcare Law Compliance at Pfizer	**
DX-37	Email from A. Greensmith to multiple recipients re: Bextra	**
DX-38	Email from D. Mahoney to multiple recipients re: Zyvox	**
DX-39	Email from J. Friedland to S. Denlinger re: Zyvox	**
DX-40	M. Abelardo Certification	**
DX-41	M. Abelardo Certification	**
DX-42	M. Abelardo Certification	**
DX-43	M. Abelardo Certification	**
DX-44	M. Abelardo Certification	**
DX-45	M. Abelardo Certification	**
DX-46	M. Abelardo Certification	**
DX-47	M. Abelardo Certification	**
DX-48	M. Abelardo Certification	**
DX-49	M. Abelardo Certification	**
DX-50	Email from L. Levy to G. Cawkwell re: Bextra	**
DY-1	COX-2 Presentation	**
DY-2	Email from A. Jenner to multiple recipients re: Bextra	**
DY-3	Memo from G. Sands to Bextra Field Force	**
DY-4	Healthcare Law Compliance at Pfizer	**
DY-5	Email from J. Zgomic to multiple recipients re: Geodon	**
DY-6	Lyrice Launch materials	**
DY-7	Email from E. Cappellino to multiple recipients re: Lyrice	**
DY-8	Email from D. Terranova to multiple recipients re: Lyrice	**
DY-9	Email from G. Duncan to P. Kelly re: Cox-2	**
DY-10	Audit Committee pre-read	**
DY-11	Email from J. Coccari to multiple recipients re: Cox-2	**
DY-12	Email from J. Fisher to multiple recipients re: Cox-2	**
DY-13	Email from L. Levy to multiple recipients re: COX-2	**
DY-14	Email from J. Martinez to multiple recipients re: compliance	**
DY-15	Letter from N. Hall to L. Snyder	**
DY-16	Letter from G. Breen to N. Hall	**
DY-17	Letter from N. Hall to G. Breen	**

Defendants' Trial Exhibit List

DY-18	Letter from G. Breen to N. Hall	**
DY-19	A. Loebel Certification	**
DY-20	A. Loebel Certification	**
DY-21	A. Loebel Certification	**
DY-22	A. Loebel Certification	**
DY-23	Email from C. Shaughnessy to multiple recipients re: Geodon	**
DY-24	Email from J. Zgombic re: Geodon	**
DY-25	Email from M. Westlock to L. Shrayner re: Geodon	**
DY-26	Email from A. Levin to D. Shedlarz re: disclosures	**
DY-27	Pfizer Form 8-K	**
DY-28	Board of Directors Minutes	**
DY-29	Legal Proceedings Disclosure Process	**
DY-30	Email from B. Bulley to D. DeShong re: Bextra	**
DY-31	Email from A. Jenner to A. Jenner re: compliance	**
DY-32	Email from T. Brandt to multiple recipients re: audit	**
DY-33	Internal Audit Report	**
DY-34	Internal Audit Report	**
DY-35	Internal Audit Report	**
DY-36	Internal Audit Report	**
DY-37	Internal Audit Report	**
DY-38	Internal Audit Report	**
DY-39	Internal Audit Report	**
DY-40	Internal Audit Report	**
DY-41	Internal Audit Report	**
DY-42	Internal Audit Report	**
DY-43	Internal Audit Report	**
DY-44	Letter from G. Elliott to J. Hankin	**
DY-45	Letter from M. Moghaddassi to K. Chitale	**
DY-46	Letter from R. Dean to R. Clark	**
DY-47	Letter from R. Clark to T. Abrams	**
DY-48	Letter from R. Clark to T. Abrams	**
DY-49	Letter from N. Chaudry to A. Moukhtara	**
DY-50	Letter from N. Chaudry to A. Moukhtara	**

Defendants' Trial Exhibit List

DZ-1	H. McKinnell and A. Levin CEO/CFO Certifications	**
DZ-2	H. McKinnell and A. Levin CEO/CFO Certifications	**
DZ-3	J. Kindler CEO Certification	**
DZ-4	A. Levin CFO Certification	**
DZ-5	A. Levin CFO Certification	**
DZ-6	J. Kindler and A. Levin CEO/CFO Certification	**
DZ-7	J. Kindler and A. Levin CEO/CFO Certification	**
DZ-8	J. Kindler and A. Levin CEO/CFO Certification	**
DZ-9	J. Kindler and F. D'Amelio CEO/CFO Certifications	**
DZ-10	J. Kindler and F. D'Amelio CEO/CFO Certifications	**
DZ-11	J. Kindler and F. D'Amelio CEO/CFO Certifications	**
DZ-12	J. Kindler and F. D'Amelio CEO/CFO Certifications	**
DZ-13	J. Kindler and F. D'Amelio CEO/CFO Certifications	**
DZ-14	J. Kindler and F. D'Amelio CEO/CFO Certifications	**
DZ-15	Letter from N. Hall to L. Snyder	**
DZ-16	Letter from G. Breen to N. Hall	**
DZ-17	Letter from N. Hall to L. Snyder	**
DZ-18	Letter from G. Breen to N. Hall	**
DZ-19	Letter from N. Hall to G. Breen	**
DZ-20	J. Kindler CEO Certification	**
DZ-21	Email from Ahrens to Linken re subpoena	**
DZ-22	Letter from Rosen to Lamberti re production	**
DZ-23	Certification of Named Plaintiff	**
DZ-24	Pfizer Form 10-K	**
DZ-25	Pfizer Form 10-K	**
DZ-26	Pfizer Form 8-K	**
DZ-27	Pfizer 2009 8-K (Wyeth Merger)	**
DZ-28	Pfizer 2009 8-K & Merger Agreement	**
DZ-29	Email from K. Jones to multiple recipients re: Compliance	*
DZ-30	Process Summary	*
DZ-31	KPMG Workpaper	*
DZ-32	Compliance Chart	*
DZ-33	KPMG Workpaper	*
DZ-34	Bextra Workplan	*

Defendants' Trial Exhibit List

DZ-35	KPMG Workpaper	*
DZ-36	KPMG Workpaper	*
DZ-37	KPMG Workpaper	*
DZ-38	Audit Committee Minutes	*
DZ-39	KPMG Workpaper	*
DZ-40	Meeting Invitation re: reserves	*
DZ-41	Email from D. Lankler to C. Wessel re: Bextra	*
DZ-42	Email from G. Giampetruzzi to D. Lankler re: disclosures	*
DZ-43	Email from L. Fox to D. Lankler re: disclosures	*
DZ-44	Email from L. Cangialosi to D. Lankler re: reserves	*
DZ-45	Letter from B O'Connor to S. Bloom	*
DZ-46	Audit Committee Minutes	*
DZ-47	Memo from A. Waxman, S. Phillips to J. Chapman	*
DZ-48	Memo from A. Waxman re: Internal Controls	*
DZ-49	Email from A. Waxman to multiple recipients re: disclosures	*
DZ-50	Email from D. Lankler to P. Brockie re: Bextra	*
DAA-1	Process Summary	*
DAA-2	Process Summary	*
DAA-3	Email from A. Kremer to multiple recipients re: report	*
DAA-4	Email from F. D'Amelio to J. Chapman re: Bextra	*
DAA-5	Email from A. Kremer to multiple recipients re: report	*
DAA-6	Letter from E. Posner to S. Bloom	*
DAA-7	Email from L. Fox to A. Levin re: disclosures	*
DAA-8	Memo from D. Lankler to Audit Committee re: compliance	*
DAA-9	Audit Committee pre-read	*
DAA-10	Email from L. Fox to multiple recipients re: disclosures	*
DAA-11	Interim Completion Document	*
DAA-12	KPMG Workpaper	Authenticity + other objections
DAA-13	KPMG Workpaper	Authenticity + other objections
DAA-14	Interim Completion Document	*
DAA-15	Letter from E. Posner to S. Bloom	**
DAA-16	Stiching Philips Pensioenfond	**
DAA-17	Letter from C. Wray to DOJ	*
DAA-18	KPMG workpaper	Authenticity + other objections

Defendants' Trial Exhibit List

DAA-19	Email from H. Donnelly to D. Lankler re: disclosures	*
DAA-20	Email from D. Townsend to multiple recipients re: disclosures	*
DAA-21	Letter from USAO to E. Posner	**
DAA-22	Memo from J. Kindler to Board of Directors re: update	*
DAA-23	Letter from B. O'Connor to M. Sullivan	*
DAA-24	KPMG Workpaper	*
DAA-25	Disclosure Committee Meeting Minutes	*
DAA-26	Disclosure Committee Meeting Minutes	*
DAA-27	Certification Meeting Minutes	*
DAA-28	Email from L. Fox, Larry to D. Lankler re: Bextra	*
DAA-29	Memo from C. Mooney re: Internal Controls	**
DAA-30	Meeting Invitation from re: Zyvox	**
DAA-31	Email from J. Friedman to multiple recipients re: Lyrica POA 1	**
DAA-32	Ropes & Gray Presentation	**
DAA-33	Letter from E. De Micco to R. Dean	**
DAA-34	KPMG Workpaper	*
DAA-35	Audit Committee pre-read	*
DAA-36	Email from M. Abelardo to C. Garrett re: Zyvox	*
DAA-37	Deficiency Evaluation	*
DAA-38	Email from K. Katen to Colleagues re: announcement	*
DAA-39	Email from C. Lewis to multiple recipients re: Geodon	*
DAA-40	Zyvox Sales Messaging Initiative and Compliance Update	*
DAA-41	Stichting Philips Pensioenfond's Investment Report	*
DAA-42	Letters to the Editor from Powers & Wunderink	*
DAA-43	Email from F. D'Amelio to multiple recipients re: Bextra	*
DAA-44	Pfizer Presentation	*
DAA-45	Bextra Presentation	*
DAA-46	Presentation to DOJ re Geodon	*
DAA-47	Stichting Philips Pensioenfond's Report	*
DAA-48	Stichting Philips Pensioenfond's Report	*
DAA-49	Notes and questions for Pfizer from BlackRock	*
DAA-50	BlackRock Report	*
DBB-1	Handwritten Notes	*
DBB-2	BlackRock Global Team Meeting Minutes	*

Defendants' Trial Exhibit List

DBB-3	Stichting Philips Pensioenfonds Report	*
DBB-4	Davis Polk Presentation	*
DBB-5	Stichting Philips Pensioenfonds Report	*
DBB-6	Stichting Philips Pensioenfonds Report	*
DBB-7	Stichting Philips Pensioenfonds Report	*
DBB-8	Stichting Philips Pensioenfonds Report	*
DBB-9	Stichting Philips Pensioenfonds Report	*
DBB-10	Stichting Philips Pensioenfonds 2009 Annual Report	*
DBB-11	Stichting Philips Pensioenfonds 2009 Annual Report (translation)	*
DBB-12	Email from K. Dowd to multiple recipients re: Lyrica	*
DBB-13	Email from J. Friedman to multiple recipients re: Lyrica	*
DBB-14	Email from B. Fleischmann to multiple recipients re: Lyrica	*
DBB-15	Geodon Presentation	*
DBB-16	Headquarters Guide	*
DBB-17	Ropes & Gray Presentation	*
DBB-18	Email from L. Farstveet to multiple recipients re: Zyvox	*
DBB-19	Zyvox Messaging Guidance	*
DBB-20	Government Investigations Pre-Read	*